Source:http://www.reactome.org/biopax/48887BiochemicalReaction1834
| Predicate | Object |
|---|---|
| rdf:type | |
| biopax3:comment |
Authored: Rothfels, K, 2012-02-09,
Edited: Rothfels, K, 2012-05-16,
FP-1039 is a soluble fusion protein consisting of the extracellular region of FGFR1c bound to the Fc region of human IgG1. It is capable of binding to a wide range of FGF ligands and thereby prevents activation of multiple FGF receptors. FP-1039 is in Phase I clinical trials in solid malignancies and in Phase II trials for patients with endometrial cancers harbouring the activating mutations S252W and P253R (reviewed in Wesche, 2011).,
Reviewed: Ezzat, S, 2012-05-15
|
| biopax3:xref | |
| biopax3:dataSource | |
| biopax3:displayName |
FP-1039 acts as a ligand-trap for FGFR2b-binding ligands in endometrial cancer
|
| biopax3:left | |
| biopax3:right |